Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 11, 2025 07:01 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25
January 25, 2024 16:05 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations

Travere Therapeutics has entered into an exclusive licensing agreement with Renalys Pharma to bring sparsentan to patients in Japan.
October 13, 2023 16:30 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsentan in FSGS 11 total abstracts accepted for...
February 17, 2023 16:04 ET | Source: Travere Therapeutics, Inc.

Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients withIgA nephropathy (IgAN)Interim results from the ongoing Phase 3 PROTECT head-to-head trial...
November 21, 2014 11:31 ET | Source: Corning Museum of Glass

Collaborative Project: Digitizing the Sybren Valkema Archive

CORNING, N.Y., Nov. 21, 2014 (GLOBE NEWSWIRE) -- Over a year ago, the RKD – Netherlands Institute for Art History began working on a collaborative digital project with the Rakow Research...